[1]. Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with CML
CANCER SCIENCE WILEY [Volume]114 [Issue]3 [Page]995 -1006 (2023/) [Reviewed] Yes
[DOI] [2]. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.
Blood [Volume]141 [Issue]10 [Page]1159 -1168 (2023/) [Reviewed] Yes
[DOI] [3]. Identification of skin-infiltrating donor lymphocytes in a case of pre-engraftment syndrome
JOURNAL OF DERMATOLOGY (2023/) [Reviewed] Yes
[DOI] [4]. Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01
CANCER SCIENCE (2023/) [Reviewed] Yes
[DOI] [5]. Characterization of endogenous markers of hepatic function in patients receiving itraconazole treatment for prophylaxis of deep mycosis
JOURNAL OF INFECTION AND CHEMOTHERAPY [Volume]29 [Issue]3 [Page]244 -249 (2023/) [Reviewed] Yes
[DOI]